Related Experiment Video

Updated: Nov 20, 2025

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.4K

[Potential therapies for COVID-19 cardiovascular complications using artemisinin and its derivatives intervene based

Yuan-Min Yang1, Li-Na Chen1, Shui-Qing Qu2

  • 1Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China Artemisinin Research Center, China Academy of Chinese Medical Sciences Beijing 100700, China.

Zhongguo Zhong Yao Za Zhi = Zhongguo Zhongyao Zazhi = China Journal of Chinese Materia Medica
|January 26, 2021
PubMed

Insights

COVID-19 causes significant cardiovascular damage. Artemisinin derivatives show promise for treating these heart complications through drug repurposing, offering cardiovascular protection.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • COVID-19 (Coronavirus Disease 2019) leads to severe cardiovascular complications, including acute myocardial injury and chronic cardiac damage.
  • Drug repurposing presents a vital strategy for developing novel therapeutics against COVID-19.
  • Artemisinin and its derivatives possess diverse pharmacological activities, with emerging evidence of cardiovascular protective effects.

Purpose of the Study:

  • To review the pathogenesis of COVID-19-induced cardiovascular damage.
  • To summarize the cardiovascular protective effects of artemisinin and its derivatives.
  • To explore the potential of artemisinin-based drugs for treating COVID-19 cardiovascular complications via drug repurposing.

Main Methods:

  • Literature review on COVID-19 pathogenesis and cardiovascular effects.
  • Analysis of research on artemisinin's pharmacological actions.
  • Evaluation of artemisinin's potential in mitigating COVID-19-related cardiovascular issues.

Main Results:

  • COVID-19 causes myocardial injury via direct viral effects, ACE2 inhibition, cytokine storms, hypoxemia, and drug side effects.
  • Artemisinin derivatives exhibit anti-arrhythmic, anti-myocardial ischemia, anti-atherosclerosis, and plaque-stabilizing properties.
  • Artemisinin's immunomodulatory, tissue-protective, and antiviral effects suggest multi-pathway intervention capabilities.

Conclusions:

  • Artemisinin-based drugs offer a promising avenue for treating cardiovascular complications associated with COVID-19.
  • Drug repurposing of artemisinins provides a novel therapeutic strategy for managing the cardiac sequelae of COVID-19.
  • Further research into artemisinins can yield new treatments for COVID-19 and its cardiovascular manifestations.

Keywords:
2019-nCoVCOVID-19artemisininartemisinin derivativescardiovascular diseasedrug repurposingheart injury

More Related Videos

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells10:33

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells

Published on: November 18, 2022

1.6K
Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation09:53

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

659

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
667
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.7K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
932
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
91
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
967
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
124